C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

Adult CIRB - Early Phase Emphasis Meeting Agenda

November 3, 2026

I New Study - Initial Review

10790, A Phase II Study of Enzomenib in Metastatic Castration-Resistant Prostate Cancer (Version Date 10/06/26)

II Amendment Prior to Activation

10760, A Phase I Study of Glofitamab with Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma (Version Date 10/01/26)

III Amendment

10433, Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors (Version Date 09/11/26)

IV Amendment

10630, Phase 1 Trial of Iadademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naive AML (Version Date 09/30/26)

V Continuing Review

10508, A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin lymphoma (HL) (Version Date 07/17/25)

VI Continuing Review

EA5162, Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR (Version Date 10/03/24)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

VII Continuing Review

10146, Randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab in patients with metastatic triple negative breast cancer (Version Date 06/03/26)

VIII Continuing Review

10449, A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer (Version Date 04/16/26)

IX Continuing Review

10495, Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations (Version Date 07/11/26)

X Continuing Review

10499, Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors (Version Date 10/20/25)

XI Continuing Review

10507, A Phase 1 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Platinum-based Chemotherapy in Patients with NUT Carcinoma (Version Date 10/29/25)

XII Continuing Review

10509, A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma, Breast Cancer and Other Solid Tumors (Version Date 04/22/26)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

XIII Continuing Review

10721, Neoadjuvant Chemotherapy with or without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study (Version Date 10/09/26)